Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:GSK
|
| gptkbp:age |
from 6 weeks
|
| gptkbp:approves |
gptkb:legislation
gptkb:2009 gptkb:United_States |
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:clinical_trial |
Phase III
preventive vaccination |
| gptkbp:contains_allergens |
gptkb:Streptococcus_pneumoniae
|
| gptkbp:contraindication |
severe allergic reaction
|
| gptkbp:dosage_form |
suspension
|
| https://www.w3.org/2000/01/rdf-schema#label |
Synflorix
|
| gptkbp:is_vulnerable_to |
gptkb:item
high global available in many countries refrigerated ongoing studies single dose improves quality of life supports public health initiatives contributes to herd immunity WHO prequalification studies on long-term immunity 3 doses conjugate vaccine reduces healthcare costs demonstrated in clinical trials reduces mortality rates CDC guidelines ACIP recommendations based on polysaccharide antigens enhances child survival rates improves child health monitored post-licensure primary series followed by booster reduces antibiotic use reduces invasive pneumococcal disease reduces otitis media reduces pneumonia incidence studies on booster doses studies on combination vaccines |
| gptkbp:manager |
intramuscular
|
| gptkbp:manufacturer |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:regulates |
regulated by health authorities
|
| gptkbp:side_effect |
headache
muscle pain fever rash drowsiness irritation at injection site loss of appetite common cold symptoms |
| gptkbp:suitable_for |
gptkb:Person
|
| gptkbp:targets |
pneumococcal disease
|